HealthEconomics.Com - The Resource for Health Outcomes Professionals

search   
Sign Up For Our Newsletter
Email:  


industry news

Direct-to-consumer communication by pharmaceutical companies ? Europeans deserve better

FDA Final Guidance on Patient-Reported Outcome (PRO) Measures: Use in Medical Product Development to Support Labeling Claims

Employers plan to shift more health-care costs to workers, survey reports By David S. Hilzenrath

Characteristics of Published Comparative Effectiveness Studies of Medication by Michael Hochman, MD; Danny McCormick, MD, MPH

International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?

Health Care Reform — Where Do We Go from Here?

"Interpreting Hazards: The Increasing Importance of "Antidote to Anecdote" in Managed Care" by Fairman et al

"Is "Value-Based" Value Wasted? Examining Value-Based Insurance Designs Through the Lens of Cost-Effectiveness" by Melnick et al

58% of Surgeries Performed in Hospitals are Outpatient, According to AHRQ/HCUP survey.

AHRQ Introduces New Online Technical Tutorial Series With First Module on HCUP Sample Design

Doctors Face 21% Cut In Medicare Payments.

AMCP Issues Summary of White House Health Care Reform Summit

Maximus To Continue Reviewing Medicare Part D Plan Coverage Determinations

Pharmacoeconomics to Get Bigger Budgets, According to Preliminary Survey Results (Source=Marketwire)

Healthcare Rationing by Proxy: Cost-Effectiveness Analysis and the Misuse of the $50,000 Threshold in the US by Bridges et al.

The AMCP Format for Formulary Submissions, Version 3.0

Statistical Data Resources from AMCP for benchmarking in managed care

UnitedHealthcare has launched an innovative program that offers $20 discounts off certain prescription drug co-payments

Healthcare Technology News: National Health Expenditures Top 17% of GDP

UnitedHealthcare Creates Adult National Cancer Care Registry with Data and Analysis to Support Oncologists in the Fight against Cancer

Novartis’s Afinitor Cancer Drug Rejected by U.K. Cost Agency

NEJM: “Giving Teeth to Comparative-Effectiveness Research — The Oregon Experience” by Saha et al.

Oncology Innovative Pricing deal with NICE on lung cancer drug

“Medication Adherence and Enrollment in a Consumer-Driven Health Plan” by Chen,

FDA News: NICE Outlines Appeals Process for Drug Determinations

IBI: More Than Health Promotion: How Employers Manage Health and Productivity

PR Hub: NICE Recommends Approval of New Rheumatoid Arthritis (RA) Treatment Cimzia(R) (certolizumab pegol) With First of its Kind RA Patient Access Scheme

Healthcare Technology News: Privacy Survey - In Providers We Trust

NEJM article: ‘ Uncomfortable Arithmetic — Whom to Cover versus What to Cover’ by K. Baicker and A. Chandra

NEJM article: ‘ “Play-or-Pay” Insurance Reforms for Employers — Confusion and Inequity’ by B. Herring and M.V. Pauly

Centre for Reviews and Dissemination: Cost-effectiveness of interventions to promote physical activity: a modelling study

Do Health Politicians Really Listen to Health Economists? Observations from Europe by Mittendorf et al.

The Hospitalist: Evidence-Based Medicine Curveball

Health Care Reform and the Need for Comparative-Effectiveness Research

January 2010 Newsletter and Eisenberg Conference Series 2009 Are Now Available

Disease Management Care Blog: 10 Predictions for the Next Decade

Conference: Patient Experience and Patient Safety Culture, April 19-21

Funny Pharmacy Videos. These are Hysterical! Particularly "The PharmG's - Boom Intervention" Rap


hot jobs

Job Title Company
Health Economist University of Cambridge, Institute of Public Health
Consultant (Health Economic Modelling) HERON Evidence Development
Health Technology and Systems Analyst Liverpool School of Tropical Medicine
Director Pharmacoeconomist SXC Health Solutions
Consultant, Marketing Research Trinity Partners


other resources

A Primer on BAYESIAN STATISTICS in Health Economics and Outcomes Research
White paper on the Bayesian Initiative in Health Economics & Outcomes Research (“The Bayesian Initiative”), formed to explore the extent to which formal Bayesian statistical analysis can and should be incorporated into the field of health economics and outcomes research for the purpose of assisting rational health care decision-making
A Selection of Statistical Process Control Tools Used in Monitoring Health Care Performance
The purpose of this article is to briefly outline some of the SPC tools available for monitoring a health care process with corresponding references to their application. (Source: Stephen Schmaltz, PhD, National Measures Clearinghouse, Nov 2009)
A Selection of Statistical Process Control Tools Used in Monitoring Health Care Performance
Statistical Control Process contains a number of graphical methods that helps achieve several objectives: quantifying one or more measures of a process; determining whether the process is operating within an acceptable range of variability; identifying ways that the process can be improved to achieve its best target value; and eliminating unacceptable variability (Source: Stephen Schmaltz, PhD, National Quality Measures Clearinghouse,Dec. 2009)
Advanced Modelling Methods for Health Economic Evaluation
A three-day course focusing on advanced modelling methods for economic evaluation. This course is a collaboration between the University of Glasgow and the Centre for Health Economics at the University of York. (Source: The University of York)
AHRQ: Innovative Adaptation and Dissemination of AHRQ Comparative Effectiveness Research Products (iADAPT)
Grant Announcements Update
An Outcomes Research (Pharmacoeconomics/Pharmacoepidemiology) Course for PharmD Students
Article summarizing course development of pharmacoeconomics and outcomes research course covering concepts, methodology, and research proposal development. (Source: David M. Scott & Craig A. Pedersen, American Journal of Pharmaceutical Education Vol. 64, Summer 2000)
Artificial Neural Network in Pharmacoeconomics
Journal article describing the use of an artificial neural network (ANN) for medical effect prediction, which could help in the extrapolation of pharmacoeconomic analysis' results. (Source: Sebastian Polak1, Agnieszka Skowron1, Aleksander Mendyk2, Jerzy Brandys, Studies in Health Technologies and Informatics, IOS Press, 2004)
Barriers to Generalizability of Health Economic Evaluations in Latin America and the Caribbean Region
Barriers to Generalizability of Health Economic Evaluations in Latin America and the Caribbean Region. (Source: PharmacoEconomics: 1 November 2009 - Volume 27 - Issue 11 - pp 919-929)
Bridging the Gap Between Pharmacoeconomics and the Real-World Practice of Managed Care Pharmacy
Article discussing specialized needs of managed care for pharmacoeconomics and outcomes data. (Source: Journal of Managed Care Pharmacy JMCP January/February 2006 Vol. 13, No. 1)
Cluster randomization in Health Outcomes Research
A PPT presentation, "Cluster randomization in Health Outcomes Research", is 59 charts in length. (Source: Institue for Health Research, August 2009)
Comparative Effectiveness Research (CER) and Pharmaceutical Companies (PPT Presentation)
Excellent overview of the use of CER and HEOR
Comparative Effectiveness Research: Relevance
Primer in AJHP by Schumock and Pickard: "Comparative Effectiveness Research: Relevance and Applications to Pharmacy" is a good basic overview. (Source: Glen T. Schumock and A. Simon Pickard, American Society of Health-System Pharmacists, Inc., 2009)
Dealing with Excessive Off-Label Drug Use: Liability vs. Patent Prolongation
This paper shows that a reinforcement of physician liability for off-label use may be the preferred instrument for achieving dynamic efficiency. (Source: Felder & Olbrich, Ruhr Economic Paper, Oct. 2009)
Disease Management Care Blog: 10 Predictions for the Next Decade
10 Predictions for the Next Decade predicts classic health economics will be replaced by a more multi-disciplinary approach including anthropology, sociology and psychology. (Source: Disease Management Care Blog, Jan. 14, 2010)
Evaluation in health outcomes research: linking theories, methodologies and practice in health promotion
Journal article covering issues, theories, methodologies, and concerns.
Evidence-Based Medicine Workbook
Based on workshops. Great resource
Evidenced-based Medicine Workbook
Evidence-based Medicine Workbook, Finding and applying the best research evidence to improve patient care. (Source: Glasziou, Del Mar, Salsbury, BMJ Books, September 2009)
Growing Application of Pharmacoeconomics and
Growing Application of Pharmacoeconomics and Outcomes Research in Health-Care Decision-Making in the Asia-Pacific Region. (Source: Bong-min Yang, PhD, and Kenneth Lee, PhD, Values in Health, Vol. 12, 2009)
Health Economics, Outcomes Research and Brand Strategy
Primer (and sales tool) covering the use of HEOR
HEALTH OUTCOMES RESEARCH: A PRIMER (White Paper)
This paper is designed to explain what these terms mean, why they are important, and how health outcomes research can lead to improvements in the health care system and ultimately to health of Americans.
Health United States 2009 Report
Health, United States, 2009 (with special emphasis on Medical Technology) is the 33rd report on the health status of the United States, prepared by Dept. HHS. The 2009 Chartbook includes 36 charts, with 14 charts illustrating medical technology. There are also 150 trend tables organized around four major subject areas: health status and determinants, health care utilization, health care resources, and health care expenditures. Disability and income/education data are included.
How to read articles about health and health care
By Alicia White. you need to interrogate the article to see what it says about the research it is reporting on. Bazian (the company I work for) has interrogated hundreds of articles for "Behind The Headlines" on the NHS health news Web site, and we’ve developed the following questions to help you figure out which articles you’re going to believe, and which you’re not.
I n n ova t i ve Pricing Ag reements to Enhance Access Pro s p e c t s
REPRODUCED FROM IMS PHARMA PRICING & REIMBURSEMENT, AUGUST 2009. There is clearly an increasing need for more innovative pricing and reimbursement agreements to help to balance the often conflicting objectives of pharmaceutical and medical technology manufacturers, payers, health technology assessors (HTA), physicians and patients. The industry faces a sustained increase in the cost of healthcare and an ever-increasing range of expensive drugs and technologies available as potential therapies. Clearly, difficult choices need to be made by payers and HTAs about which products receive funding from increasingly restricted healthcare budgets, especially with often insufficient clinical and real-life evidence available. In terms of innovative agreements, more manufacturers, in more countries, are proposing risk-sharing and value-based schemes more often.
Improving Quality of Care and Outcomes: The Need and Application of Pharmacoeconomics within Geriatric Populations (PPT Presentation)
Includes the role of pharmacoeconomics specific to quality, access, and cost; the clinical and economic burden of drug-related problems; methodological issues; value for pharmaceutical interventions; applications; and research gaps within geriatric populations. (Source: Grant H. Skrepnek, Ph.D., M.S., R.Ph. The University of Arizona College of Pharmacy Center for Health Outcomes and PharmacoEconomic Research)
Integer/Linear Mathematical Programming Models: A Tool for Allocating Healthcare Resources
Budget allocations, such as formulary, drug development, and pricing decisions may benefit greatly from the use of mathematical programs.
ISPOR HEALTH ECONOMETRICS & HEALTH OUTCOMES STATISTICS SPECIAL INTEREST GROUP
The HEWG leadership group is developing an index of free online pharmacoeconomic & outcomes research software including health econometric code for statistical applications for the ISPOR website. (Source: ISPOR)
ISPOR Health Outcomes Research Index of Open Source Code
The primary purposes of the ISPOR Health Outcomes Research Index of Open Source Code are to promote estimator transparency and to clarify alternative approaches in health econometric research. Estimator transparency refers to open source code, where all relevant code is accessible, interpretable, operational, and modifiable for alternative use. This Index of Open Source Code is composed of brief descriptions and hyperlinks to open-source code that can be downloaded for free [at the time of publication in this index]. Proprietary code and code for in silico experiments (e.g., simulations) are excluded from the index. The Index of Open Source Code is arranged according to Topic [Treatment Effects, Health Costs, Health Care Utilization, Quality of Life and Utility, Censoring and Survival, Other], Sub-Topics as given below and Base Software.
ISPOR: PHARMACOECONOMICS: Identifying the Issues
This paper summarizes the results of an interdisciplinary conference to identify the issues in conducting pharmacoeconomic studies, interpreting the results of these studies, and using pharmacoeconomic information in health care decisions. (Source: Advisory Board & Marilyn Dix Smith PhD, ISPOR, 1998)
It's Time to Embrace Evidence-Based Medicine
This short article helps to define and explore EBM. (Source: Andrew Mcafee, HBR, Nov. 2009)
Malpractice Standards of Care and Regional Variations in Physician Practice Styles
This paper shows how current malpractice laws encourage physicians to follow local standards versus national standard-of-care laws, and thus lead to divergent practices. (Source: Michael Frakes, SSRN, Oct 2009)
Median Model Of U.S. EQ-5D Health State Preferences
The article describes a study where a health status questionnaire was conducted, its interpretation and use. (Source: Medical New Today, Dec. 2, 2009)
Pharmacoeconomics – an aid to better decision-making
Summary of a workshop to define pharmacoeconomic concepts and terminology. (Source: JEADV(2005)19(Suppl. 1), 34–39
Pharmacoeconomics - the importance for pharmacists
Basic overview of the use of pharmacoeconomics and outcomes research data for pharmacists
Pharmacoeconomics and Quality of Life: Evaluating the Economic and Social Impact of Pharmaceuticals
Journal article covering the basic issues and use of pharmacoeconomics, outcomes research, and patient-reported outcomes data from an individual and societal perspective.
Pharmacoeconomics Preparation Exam, from the Council for Continuing Pharmaceutical Education
Questions included in the exam. Good overview of relevant issues.
Pharmacoeconomics Summary: PowerPoint Presentation
Excellent basic overview of pharmacoeconomics by Dr. Henry Glick, University of Pennsylvania. Includes basic concepts, cost effectiveness analysis, sampling uncertainty, sample size estimation, and other special topics.
Pharmacoeconomics to Get Bigger Budgets, According to Preliminary Survey Results
This year, drug makers' pharmacoeconomics groups will spend more money than ever before -- a clear sign of the function's growing importance to success in the pharmaceutical and biotechnology sectors. (Source: Marketwire, 2/15/2010)
PHARMACOECONOMICS: PRINCIPLES, CONCEPTS & PRACTICE (PPT Presentation)
Basic overview (Source: Mohamed Izham Mohamed Ibrahim, PhD, Prof.)
Presentation: ISPOR Russia Chapter Forum: Drug Provisions for the Population of the Russian Federation
Click to see PPT Presentation
QALYs in Health Outcomes Research: Representation of Real Preferences or Another Numerical Abstraction?
Journal article on the benefits and issues related to quality adjusted life years (QALY)
Statistical Data Resources
The Academy of Managed Care Pharmacy (AMCP) has identified major benchmarking data publications that are commonly used within the managed care environment. (Source: Academy of Managed Care Pharmacy)
Statistical Data Resources
The Academy of Managed Care Pharmacy (AMCP) has identified major benchmarking data publications that are commonly used within the managed care environment. These include downloadable PDFs of topics such as: ·Benchmarking New Frontiers in Managed Care Pharmacy ·Biotechnology Monitor & Survey - Marketplace Policies, Practices, and Perspectives ·CVS Caremark Trend Rx Report 2008 ·EMD Serono Injectable Digest 5th Edition ·Express-Scripts Drug Trend Report 2008 ·Kaiser Family Foundation Prescription Drug Trends
The Fourth Hurdle: Pharmacoeconomics
Journal article describing the use of pharmacoeconomics as a life cycle management tool. (Source: Denise Mysoko, PharmaVoice, May 2008)
The New Four P's of Marketing
Remember the 4-P's of Marketing (product, placement, price, and promotion)? PharmExec.Com suggests these have been replaced by 4 New P's: Predictive Modeling, Personalization, Peer-to-Peer, Participation. According to the author, " Merely driving demand doesn't work anymore. The key to success in this new marketing landscape is a shift from a pharmaceutical-driven, push-based model toward a pull-based model, where desire for information and education drives action on the part of consumers and medical professionals." (Source: John Gardner, PharmaExec, Dec. 9, 2009)
The Pharmacoeconomics Outlook: Turning value-for-money requirements into a competitive advantage (PPT Presentation)
Basic overview, regulatory issues, case studies on valuation, including NICE. (Source: Business Insights, 2003)
The role of pharmacoeconomics in Pharmaceuticals Pricing Board decision-making (PPT Presentation)
Discusses Pharmaceuticals Pricing Board, decision-making in the PPB, and health economic evaluations in decision-making
Translation & Linguistic Validation of PRO Measures
A for fee audio conference describing best practices for Translation and Linquistic Validation of PRO measures.
Why should economic evaluations of medical innovations have a societal perspective?
Downloadable free report: Why should economic evaluations of medical innovations have a societal perspective? (Source: OHE, Office of Health Economics, published Oct. 2009)




 

Insurance Resources: Even healthy people need life insurance.
Get life insurance quotes today.

Shop and compare insurance quotes online

 

sponsored by































Become a sponsor



How are we doing? Take our survey





Copyright © 2007, HealthEconomics.Com